Scholarlink

<p>Degenerative musculoskeletal diseases such as osteoporosis (OP), osteoarthritis (OA), and intervertebral disc degeneration (IVDD) represent a growing global health challenge, causing disability, pain, and socioeconomic burden. Traditional therapies remain largely palliative, underscoring the urgent need for regenerative approaches. Mesenchymal stem cells (MSCs) are promising tools due to their capacity for multilineage differentiation, immunomodulation, and paracrine signaling. However, challenges including heterogeneity, low engraftment, and manufacturing complexity limit their clinical translation. Increasingly, extracellular vesicles (EVs) derived from MSCs have been recognized as the principal mediators of their therapeutic effects. MSC-derived-EVs (MSC-EVs) provide a safer, cell-free platform capable of regulating immune responses, promoting tissue regeneration, and delivering bioactive cargos that restore bone, cartilage, and disc homeostasis. Preclinical and early clinical data highlight their potential as next-generation therapeutics. The aim of this review is to provide valuable insights into the development and evaluation of MSCs and MSC-EVs in OA, OP, and IVDD thereby accelerating clinical translation and improving patient outcomes.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases

  • 期刊论文

  • 发表日期：

    2026年3月7日

查看全文
  • Nawaz Khan,
  • Zeynab Ahmadova,
  • Bin Zeng,
  • Waqas Ahmed,
  • Tayyab Shafiq,
  • Zihao Zhang,
  • Aiyuan Su,
  • Nazim Muhammad,
  • Sajid Khan,
  • Yujie Liang,
  • Li Duan

摘要

Degenerative musculoskeletal diseases such as osteoporosis (OP), osteoarthritis (OA), and intervertebral disc degeneration (IVDD) represent a growing global health challenge, causing disability, pain, and socioeconomic burden. Traditional therapies remain largely palliative, underscoring the urgent need for regenerative approaches. Mesenchymal stem cells (MSCs) are promising tools due to their capacity for multilineage differentiation, immunomodulation, and paracrine signaling. However, challenges including heterogeneity, low engraftment, and manufacturing complexity limit their clinical translation. Increasingly, extracellular vesicles (EVs) derived from MSCs have been recognized as the principal mediators of their therapeutic effects. MSC-derived-EVs (MSC-EVs) provide a safer, cell-free platform capable of regulating immune responses, promoting tissue regeneration, and delivering bioactive cargos that restore bone, cartilage, and disc homeostasis. Preclinical and early clinical data highlight their potential as next-generation therapeutics. The aim of this review is to provide valuable insights into the development and evaluation of MSCs and MSC-EVs in OA, OP, and IVDD thereby accelerating clinical translation and improving patient outcomes.

Graphical Abstract